Literature DB >> 21748331

Deciphering the binding mode of Zolpidem to GABA(A) α₁ receptor - insights from molecular dynamics simulation.

R S K Vijayan1, Dhananjay Bhattacharyya, Nanda Ghoshal.   

Abstract

To investigate the binding mode of Zolpidem to GABA(A) and to delineate the conformational changes induced upon agonist binding, we carried out atomistic molecular dynamics simulation using the ligand binding domain of GABA(A) α(1) receptor. Comparative molecular dynamics simulation of the apo and the holo form of GABA(A) receptor revealed that γ(2)/α(1) interface housing the benzodiazepine binding site undergoes distinct conformational changes upon Zolpidem binding. We notice that C loop of the α(1) subunit experiences an inward motion toward the vestibule and the F loop of γ(2) sways away from the vestibule, an observation that rationalizes Zolpidem as an alpha1 selective agonist. Energy decomposition analysis carried out was able to highlight the important residues implicated in Zolpidem binding, which were largely in congruence with the experimental data. The simulation study disclosed herein provides a meaningful insight into Zolpidem-GABA(A)R interactions and helps to arrive at a binding mode hypothesis with implications for drug design.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21748331     DOI: 10.1007/s00894-011-1142-0

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  28 in total

1.  Molecular and neuronal substrate for the selective attenuation of anxiety.

Authors:  K Löw; F Crestani; R Keist; D Benke; I Brünig; J A Benson; J M Fritschy; T Rülicke; H Bluethmann; H Möhler; U Rudolph
Journal:  Science       Date:  2000-10-06       Impact factor: 47.728

Review 2.  The safety and tolerability of zolpidem--an update.

Authors:  G Darcourt; D Pringuey; D Sallière; J Lavoisy
Journal:  J Psychopharmacol       Date:  1999       Impact factor: 4.153

3.  Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation.

Authors:  Araz Jakalian; David B Jack; Christopher I Bayly
Journal:  J Comput Chem       Date:  2002-12       Impact factor: 3.376

4.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Authors:  Alexander W Schüttelkopf; Daan M F van Aalten
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-07-21

Review 5.  Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins.

Authors:  A Karlin; M H Akabas
Journal:  Neuron       Date:  1995-12       Impact factor: 17.173

6.  HOLE: a program for the analysis of the pore dimensions of ion channel structural models.

Authors:  O S Smart; J G Neduvelil; X Wang; B A Wallace; M S Sansom
Journal:  J Mol Graph       Date:  1996-12

7.  Development and validation of a genetic algorithm for flexible docking.

Authors:  G Jones; P Willett; R C Glen; A R Leach; R Taylor
Journal:  J Mol Biol       Date:  1997-04-04       Impact factor: 5.469

8.  Two tyrosine residues on the alpha subunit are crucial for benzodiazepine binding and allosteric modulation of gamma-aminobutyric acidA receptors.

Authors:  J Amin; A Brooks-Kayal; D S Weiss
Journal:  Mol Pharmacol       Date:  1997-05       Impact factor: 4.436

9.  Essential dynamics of proteins.

Authors:  A Amadei; A B Linssen; H J Berendsen
Journal:  Proteins       Date:  1993-12

10.  Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different.

Authors:  Susan M Hanson; Elaine V Morlock; Kenneth A Satyshur; Cynthia Czajkowski
Journal:  J Med Chem       Date:  2008-11-27       Impact factor: 7.446

View more
  1 in total

1.  Flavonoid Myricetin Modulates GABA(A) Receptor Activity through Activation of Ca(2+) Channels and CaMK-II Pathway.

Authors:  Xiao Hu Zhang; Ze Gang Ma; Dewi Kenneth Rowlands; Yu Lin Gou; Kin Lam Fok; Hau Yan Wong; Mei Kuen Yu; Lai Ling Tsang; Li Mu; Lei Chen; Wing Ho Yung; Yiu Wa Chung; Bei Lin Zhang; Hua Zhao; Hsiao Chang Chan
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-11       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.